Sutro Biopharma - STRO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.13
  • Forecasted Upside: 228.59%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$3.69
▲ +0.14 (3.94%)

This chart shows the closing price for STRO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sutro Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STRO

Analyst Price Target is $12.13
▲ +228.59% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Sutro Biopharma in the last 3 months. The average price target is $12.13, with a high forecast of $17.00 and a low forecast of $8.00. The average price target represents a 228.59% upside from the last price of $3.69.

This chart shows the closing price for STRO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 8 contributing investment analysts is to buy stock in Sutro Biopharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/12/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/10/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/8/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/8/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/6/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/5/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2024

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/11/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$11.00 ➝ $11.00
10/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
9/16/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$17.00 ➝ $17.00
9/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
8/16/2024Truist FinancialLower TargetBuy ➝ Buy$18.00 ➝ $15.00
8/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
5/15/2024OppenheimerReiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.00
5/14/2024WedbushReiterated RatingOutperform ➝ Outperform$8.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00
5/8/2024Bank of AmericaInitiated CoverageBuy$12.00
4/30/2024WedbushReiterated RatingOutperform$8.00
4/3/2024WedbushReiterated RatingOutperform$8.00
4/3/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$12.00 ➝ $11.00
4/3/2024Truist FinancialLower TargetBuy ➝ Buy$25.00 ➝ $18.00
4/3/2024OppenheimerReiterated RatingOutperform ➝ Outperform$10.00
4/3/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$17.00
3/27/2024OppenheimerReiterated RatingOutperform ➝ Outperform$10.00
3/26/2024WedbushLower TargetOutperform ➝ Outperform$12.00 ➝ $8.00
3/26/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$17.00
3/26/2024HC WainwrightLower TargetBuy ➝ Buy$16.00 ➝ $12.00
1/5/2024WedbushReiterated RatingOutperform$12.00
11/15/2023Piper SandlerLower TargetOverweight ➝ Overweight$18.00 ➝ $12.00
11/14/2023WedbushReiterated RatingOutperform$12.00
11/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$16.00
11/9/2023Deutsche Bank AktiengesellschaftInitiated CoverageBuy$12.00
10/23/2023WedbushReiterated RatingOutperform ➝ Outperform$12.00
10/5/2023OppenheimerInitiated CoverageOutperform$10.00
9/6/2023Truist FinancialReiterated RatingBuy ➝ Buy$25.00
8/14/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$17.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$16.00
8/11/2023WedbushLower TargetOutperform ➝ Outperform$20.00 ➝ $12.00
4/3/2023JMP SecuritiesLower TargetOutperform$20.00 ➝ $17.00
3/31/2023WedbushReiterated RatingOutperform$20.00
3/31/2023HC WainwrightLower TargetBuy$20.00 ➝ $16.00
3/21/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$15.00 ➝ $8.00
1/13/2023Truist FinancialBoost TargetBuy$21.00 ➝ $25.00
1/10/2023Piper SandlerBoost TargetOverweight$16.00 ➝ $18.00
11/9/2022HC WainwrightLower TargetBuy$30.00 ➝ $20.00
8/23/2022Truist FinancialLower TargetBuy$37.00 ➝ $21.00
8/18/2022Wells Fargo & CompanyReiterated RatingOverweight$15.00
7/6/2022JMP SecuritiesReiterated RatingBuy$20.00
7/4/2022Piper SandlerBoost Target$16.00
6/28/2022Piper SandlerBoost Target$14.00 ➝ $16.00
6/6/2022JMP SecuritiesReiterated RatingBuy$20.00
5/23/2022Piper SandlerLower TargetOverweight$29.00 ➝ $14.00
5/11/2022HC WainwrightLower Target$35.00 ➝ $30.00
5/10/2022WedbushLower Target$30.00 ➝ $20.00
4/11/2022JMP SecuritiesReiterated RatingBuy$20.00
3/7/2022JMP SecuritiesLower Target$28.00 ➝ $20.00
1/6/2022WedbushLower Target$37.00 ➝ $30.00
11/17/2021Berenberg BankInitiated CoverageBuy$30.00
10/1/2021Wells Fargo & CompanyReiterated RatingBuy$30.00
6/22/2021JMP SecuritiesReiterated RatingBuy$28.00
6/18/2021HC WainwrightInitiated CoverageBuy$35.00
1/28/2021Truist FinancialBoost Target$24.00 ➝ $37.00
12/2/2020Stifel NicolausInitiated CoverageBuy$25.00
11/6/2020Piper SandlerBoost TargetOverweight$20.00 ➝ $22.00
9/2/2020Jefferies Financial GroupInitiated CoverageBuy$21.00
7/16/2020Wells Fargo & CompanyInitiated CoverageOverweight$18.00
5/18/2020Piper SandlerLower Target$23.00 ➝ $20.00
5/13/2020HC WainwrightLower TargetBuy$18.00 ➝ $17.00
5/12/2020B. RileyDowngradeHold
3/17/2020HC WainwrightReiterated RatingBuy$18.00
3/16/2020CowenReiterated RatingBuy
1/13/2020SunTrust BanksInitiated CoverageBuy$18.00
(Data available from 11/5/2019 forward)

News Sentiment Rating

0.62 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/9/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/9/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
6/8/2024
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/8/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/7/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/6/2024
  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/6/2024
  • 6 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/5/2024

Current Sentiment

  • 6 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Sutro Biopharma logo
Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $3.69
Low: $3.36
High: $3.72

50 Day Range

MA: $3.87
Low: $3.25
High: $4.96

52 Week Range

Now: $3.69
Low: $2.01
High: $6.13

Volume

801,464 shs

Average Volume

811,765 shs

Market Capitalization

$302.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17

Frequently Asked Questions

What sell-side analysts currently cover shares of Sutro Biopharma?

The following Wall Street research analysts have issued stock ratings on Sutro Biopharma in the last twelve months: Bank of America Co., Deutsche Bank Aktiengesellschaft, HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., Piper Sandler, Truist Financial Co., and Wedbush.
View the latest analyst ratings for STRO.

What is the current price target for Sutro Biopharma?

8 Wall Street analysts have set twelve-month price targets for Sutro Biopharma in the last year. Their average twelve-month price target is $12.13, suggesting a possible upside of 228.6%. JMP Securities has the highest price target set, predicting STRO will reach $17.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $8.00 for Sutro Biopharma in the next year.
View the latest price targets for STRO.

What is the current consensus analyst rating for Sutro Biopharma?

Sutro Biopharma currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STRO will outperform the market and that investors should add to their positions of Sutro Biopharma.
View the latest ratings for STRO.

What other companies compete with Sutro Biopharma?

How do I contact Sutro Biopharma's investor relations team?

Sutro Biopharma's physical mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company's listed phone number is (650) 392-8412 and its investor relations email address is [email protected]. The official website for Sutro Biopharma is www.sutrobio.com. Learn More about contacing Sutro Biopharma investor relations.